【摘要】 目的探讨单倍型骨髓移植治疗血液系统恶性组织细胞病(恶组)的造血重建、移植相关并发症的发生。方法对1例20岁男性恶组患者进行单倍型骨髓移植,供者为患者之父,HLA2个位点不合。预处理方案:采用白消安加环磷酰胺(Bu/Cy)方案,加用抗淋巴细胞球蛋白(ALG)。移植物抗宿主病(GVHD)的预防采用环孢菌素A(CsA)联合短程甲氨蝶呤(MTX)和骁悉(MMF)的方案,移植有核细胞数为4.3×108/kg。结果移植后+20天中性粒细胞数>0.5×109/L,移植后+25天血小板计数>20×109/L,移植后+46天全血细胞恢复正常。移植后2个月血型由O型转为A型。结论单倍型骨髓移植治疗恶性组织细胞病是可行的。更多还原

【Abstract】 Objective To explore the hematopoietic reconstitution and transplantation related complications of haploidentical bone marrow transplantation for treatment of malignant histiocytosis. Method A 20- year- old male patient with malignant histiocytosis received haploidentical allo- BMT from HLA 2 loci mismatched related donor, his father. Conditioning regimen consisted of Bu- CTX plus ALG. The regimen of CSA and MMF and short course of MTX were used for GVHD prophylaxis.The number of nucleated cells in graft was 4.3×108/L. Results ANC rose to 0.5×109/L on day+20. BPC rose to 20×109/L on day+25. The normalization of peripheral blood counts occurred on day+40. The conversion of blood group from type O to A occurred on day+60. Conclusions Haploidentical bone marrow transplantation is feasible for the treatment of patients with malignant histiocytosis.更多还原